Login to Your Account



BACIT Aims for $404M Raise for Cancer Drug Development

By Nuala Moran
Staff Writer

Wednesday, October 3, 2012
LONDON – A group of leading UK fund managers is aiming to raise £250 million (US$404 million) in the initial public offering of the Battle Against Cancer Investment Trust (BACIT), a new style of fund that intends to invest 1 percent of its net asset value (NAV) per year in drug development programs originating at the Institute of Cancer Research (ICR), London.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription